BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 144.03 |
| Open | 141.50 |
| Bid | 131.88 x 1200 |
| Ask | 139.04 x 900 |
| Day's Range | 136.85 - 142.20 |
| 52 Week Range | 118.18 - 392.30 |
| Volume | |
| Avg. Volume | 232,041 |
| Market Cap | 14.589B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.05 |
| Earnings Date | Aug 08, 2018 - Aug 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 271.64 |
- Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have
- Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment o
- Business Wire
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 10, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
